CA
NTLA icon

CastleArk Alternatives’s Intellia Therapeutics NTLA Stock Holding History

CastleArk Alternatives’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-39,020
Closed -$5.24M – 193
2021
Q3 		$5.24M Buy
+39,020
New +$5.91M 0.2% 120

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CastleArk Alternatives's NTLA Position: Q4 2021 in Review

CastleArk Alternatives sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 39,020 shares — an estimated $5.24M sold.

CastleArk Alternatives first reported a position in NTLA in Q3 2021 and held it in 1 quarter. The position peaked at $5.24M in Q3 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • CastleArk Alternatives reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 39,020 Intellia Therapeutics shares in Q4 2021, an estimated $5.24M.
  • CastleArk Alternatives first reported a position in Intellia Therapeutics in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Intellia Therapeutics position peaked at $5.24M in Q3 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.